Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
None (51) ·
(none, never marketed) (1) ·
Benzedrex (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
Sunosi (1) ·
THIP (1) ·
Versed (1) ·
Wakix (1) ·
Xyrem (1)
mechanism:
GABAA positive allosteric modulator (15) ·
Monoamine releasing agent (8) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
None (3) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
GABAA potentiator and direct activator (2) ·
Melatonin receptor agonist (2) ·
Norepinephrine–dopamine reuptake inhibitor (2)
None (72) ·
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1)
None (72) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. (1)
None (72) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited data; pitolisant may reduce hormonal contraceptive efficacy (1) ·
Limited data; pregnancy exposure registry available (1)
Showing below up to 75 results in range #1 to #75.


